Strategic Alliance Leverage Bioverativ's integration within Sanofi to accelerate commercialization of hemophilia and rare blood disorder therapies through Sanofi's global distribution, payer access, and commercial networks.

Hemophilia Focus Capitalize on the company's core focus to pursue cross selling of related services such as diagnostics support, patient engagement programs, and real-world evidence collaborations that can broaden therapy adoption.

Gene Therapy Potential Build on the existing LentiVector collaboration with Oxford Biomedica by pursuing licensing or co-development of gene therapy approaches for hemophilia, including manufacturing partnerships and supply chain readiness.

Agile Partner Target mid-sized biotech collaboration opportunities that benefit from quick decision cycles, flexible deal structuring, and asset-specific milestones suitable for pilot programs or early-stage assets within a larger corporate framework.

Community Access Utilize Bioverativ's active engagement with the blood disorders community to co-create patient-centric access programs, advocacy partnerships, and payer strategies that differentiate offerings and accelerate reimbursement.